{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:41:41Z","timestamp":1784238101642,"version":"3.55.0"},"reference-count":42,"publisher":"Scientific Scholar","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background &amp; objectives:<\/jats:title>\n            <jats:p>The role of consolidation radiation therapy (CRT) after complete metabolic response to chemotherapy in advanced-stage (stage III and IV) Hodgkin lymphoma (HL) is controversial. This study was undertaken to assess the clinical outcomes in terms of event free survival, local failure free survival and overall survival in individuals with advanced HL treated with chemotherapy and CRT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective review was conducted to study the long-term clinical outcomes in individuals diagnosed with HL and treated with chemotherapy and CRT from 2012 to 2016 at a tertiary cancer care hospital in India.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Data from 203 study participants with advanced-stage HL were analyzed. Positron emission tomography-computed tomography (PET-CT) was done at baseline and after 2 cycles for response assessment. The median age at presentation was 32 yr [interquartile range (IQR): 26-46]. Early metabolic response (after 2 cycles) and delayed metabolic response (after 4 or 6 cycles) were observed in 74.4 and 25.6 per cent of individuals, respectively. With a median follow up of 52 months (IQR: 40-67), the five-year event-free survival (EFS), local failure-free survival (LFFS) and overall survival (OS) were 83.2, 95.1 and 94.6 per cent, respectively. On univariate analysis, extranodal disease was associated with inferior EFS (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.043). Haemoglobin &lt;10.5 g\/dl (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.002) and Hasenclever index &gt;3 (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.00047) were associated with poorer OS. Relapses were observed in 28\/203 (13.8%) study participants with predominance at central nodal stations. The median time to relapse was 19.4 months (IQR: 13-33). Local relapse alone (at the irradiated site) was observed in 5\/28 study participants, systemic (distant) relapse in 14\/28 individuals, while both systemic and local relapse was observed in 9\/28 participants. Extranodal disease (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.05), bulky disease (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.005) and haemoglobin concentration \u226410.5 g\/dl (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.036) were significant predictors for disease relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation &amp; conclusions:<\/jats:title>\n            <jats:p>Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_3459_21","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T09:32:19Z","timestamp":1712655139000},"page":"193-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study"],"prefix":"10.25259","volume":"159","author":[{"given":"Swati","family":"Chugh","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutam","family":"Panda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruti","family":"Mokal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Epari","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Secretariat, Tata Memorial Centre, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Khattry","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Sengar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Laskar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant S.","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hematolymphoid Disease Management Group, Tata Memorial Center, BARC Training School Complex, Mumbai, Maharashtra, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"R1-20241212","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/PPO.0b013e31819e30d7","article-title":"Late effects of Hodgkin's disease and its treatment","volume":"15","author":"Ng","year":"2009","journal-title":"Cancer J"},{"key":"R2-20241212","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-20241212","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"R4-20241212","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma:10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"R5-20241212","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18):Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"R6-20241212","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial):A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"R7-20241212","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.radonc.2018.06.033","article-title":"Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy","volume":"129","author":"Moding","year":"2018","journal-title":"Radiother Oncol"},{"key":"R8-20241212","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20241212","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1200\/JCO.20.00935","article-title":"Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD:Final analysis of the randomized GITIL\/FIL HD0607 trial","volume":"38","author":"Gallamini","year":"2020","journal-title":"J Clin Oncol"},{"key":"R10-20241212","first-page":"3035","article-title":"Effect of radiation therapy on survival in Hodgkin's lymphoma:A SEER data analysis","volume":"37","author":"Master","year":"2017","journal-title":"Anticancer Res"},{"key":"R11-20241212","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma:Survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"R12-20241212","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/JBM.S69267","article-title":"The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy","volume":"6","author":"Bayoumi","year":"2015","journal-title":"J Blood Med"},{"key":"R13-20241212","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/BLCTT.S160404","article-title":"Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era","volume":"8","author":"Lapuz","year":"2018","journal-title":"Blood Lymphat Cancer"},{"key":"R14-20241212","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1008362700606","article-title":"Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma:A two centre study","volume":"11","author":"Shamash","year":"2000","journal-title":"Ann Oncol"},{"key":"R15-20241212","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma:Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20241212","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma:A question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-20241212","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-20241212","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R19-20241212","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cncr.21587","article-title":"Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma","volume":"106","author":"Kuruvilla","year":"2006","journal-title":"Cancer"},{"key":"R20-20241212","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin's lymphoma:Meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann Oncol"},{"key":"R21-20241212","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International database on Hodgkin's disease overview study group","volume":"16","author":"Loeffler","year":"1998","journal-title":"J Clin Oncol"},{"key":"R22-20241212","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2005-11-4429","article-title":"Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma:A study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"107","author":"Ferm\u00e9","year":"2006","journal-title":"Blood"},{"key":"R23-20241212","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy:Is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"J Clin Oncol"},{"key":"R24-20241212","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma:An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"R25-20241212","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma:United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R26-20241212","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/annonc\/mdp337","article-title":"Stanford V program for locally extensive and advanced Hodgkin lymphoma:The Memorial Sloan-Kettering cancer center experience","volume":"21","author":"Edwards-Bennett","year":"2010","journal-title":"Ann Oncol"},{"key":"R27-20241212","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease:Report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"key":"R28-20241212","first-page":"1","article-title":"Does interim PET scan after 2 cycles of ABVD predict outcome in Hodgkin lymphoma?Real-world evidence","volume":"5","author":"Seshachalam","year":"2019","journal-title":"J Glob Oncol"},{"key":"R29-20241212","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjh.16289","article-title":"Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting","volume":"188","author":"Korula","year":"2020","journal-title":"Br J Haematol"},{"key":"R30-20241212","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma","volume":"26","author":"Ganesan","year":"2015","journal-title":"Ann Oncol"},{"key":"R31-20241212","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"R32-20241212","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging:Southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"R33-20241212","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R34-20241212","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R35-20241212","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"R36-20241212","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse:Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"R37-20241212","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1148\/radiol.2373040555","article-title":"Direct comparison of FDG PET and CT findings in patients with lymphoma:Initial experience","volume":"237","author":"Tatsumi","year":"2005","journal-title":"Radiology"},{"key":"R38-20241212","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00259-003-1266-2","article-title":"From PET detectors to PET scanners","volume":"30","author":"Humm","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R39-20241212","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term overall survival and toxicities of ABVD versus BEACOPP in advanced Hodgkin lymphoma:A pooled analysis of four randomized trials","volume":"9","author":"Andr\u00e9","year":"2020","journal-title":"Cancer Med"},{"key":"R40-20241212","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/jayao.2020.0061","article-title":"Hodgkin lymphoma in adolescent and young adults:Real-world data from a single tertiary cancer center in India","volume":"10","author":"Nayak","year":"2021","journal-title":"J Adolesc Young Adult Oncol"},{"key":"R41-20241212","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"R42-20241212","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1634\/theoncologist.12-2-156","article-title":"Salvage therapy in Hodgkin's Lymphoma","volume":"12","author":"Byrne","year":"2007","journal-title":"Oncologist"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_3459_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:52:14Z","timestamp":1751464334000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_3459_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_3459_21","relation":{},"ISSN":["0971-5916","0975-9174"],"issn-type":[{"value":"0971-5916","type":"print"},{"value":"0975-9174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2021-12-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}